Journal ArticleOPEN ACCESS

"Companion diagnostics": Has their time come and gone?

Clinical Cancer Research (2014) 20(17) 4422-4424
DOI: 10.1158/1078-0432.CCR-14-0932
19Citations
Citations of this article
37Readers
Mendeley users who have this article in their library.

Abstract

Rapid development of molecularly targeted drugs requires a "companion diagnostic" that could delay drug development and limit availability of active drugs for relevant patients. Were the negative results from MetMab studies in patients with advanced non-small cell lung cancer due to drug failure or failure of the right companion diagnostic?

Cite

CITATION STYLE

APA

Hirsch, F. R., Bunn, P. A., & Herbst, R. S. (2014). “Companion diagnostics”: Has their time come and gone? Clinical Cancer Research, 20(17), 4422–4424. https://doi.org/10.1158/1078-0432.CCR-14-0932

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free